Valneva - Investment medium/long term

Here is the file type which me please on the stock market, a decorrelee society of the CAC40, with reference shareholders, an attractive bullish potential and a base that comes to create on the lowest historical of the title.

Latest news: "Valneva Thursday morning announced the success of its capital increase of 40.2 million euros. As expected, the strategic investment Fund (FSI) acquired on this occasion 10.1% of the share capital of this company, born in December last and from the approximation of Vivalis French biotechnology group with his Austrian counterpart Intercell. In scholarship, the title rose by 0.93% to 3.25 euros. An increase which cannot make us forget the chaotic course of value since the beginning of the year.

The capitalization of Valneva has indeed melted in half since the announcement of this capital increase, made on the occasion of the merger. Believing that this operation posed a risk of dilution, shareholders preferred out of a title that was at the time more than 7 euros.

The operation presented June 13 indeed proved highly dilutive with the creation of more than 15 million new shares representing 38.5% of the share capital of Valneva on that date. The offered discount was also significant with a lower subscription price of 42.5% at the closing of the action on 11 June.

Now Valneva, held at 21.7% by Groupe Grimaud, has the means to accelerate the commercialization of its vaccine against Japanese encephalitis Ixario (from 35 to 55 000 annual cases). The Group may also pursue the development of the portfolio of vaccines in experimental phase inherited Intercell (flu H1N1, various infections, Lyme disease).

On its 2013 perspectives, Valneva table on a turnover in the order of EUR 35 million. More optimistic, Portzamparc aims this year a turnover of 37.5 million to 66.2 million in 2014. Highlighting the potential rebound of the title, the broker recommends buy Valneva, with a price of 7 euros target."

The long term there is the lowest positive test.

In daily you will notice the increase in volumes, it does not lie generally.

Conclusion: buy this title around €3 to cover 50% of increase in term seems feasible.

Nota bene: this type of trade can last 2 to 5 years, this action looks like Cerep that I had given in 2012 to €1.3 it took to wait more than a year before a takeover bid at € 2.

View the original article here